Foghorn Therapeutics vs Nanobiotix
Nanobiotix is the larger business, with $36.9m of revenue in fiscal 2025 against $30.9m for Foghorn Therapeutics (1.2 times as much). Foghorn Therapeutics grew faster (36.8% against -573.6%). Nanobiotix kept more of each dollar of sales as profit: a net margin of -73.5% against -240.3%.
| Latest fiscal year | Foghorn TherapeuticsFHTX, 2025 | NanobiotixNBTX, 2025 |
|---|---|---|
| Revenue | $30.9m | $36.9m |
| Revenue growth | 36.8% | -573.6% |
| Net income | −$74.3m | −$27.1m |
| Operating margin | -279.5% | -33.2% |
| Net margin | -240.3% | -73.5% |
| Return on equity | — | — |
| Free cash flow | −$86.1m | −$38.4m |
| Cash | $80.9m | $61.9m |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 106 | — |
| Market value | $124m | $1.37bn |
| Price vs our value range | — | — |
| Moat score | 14 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |